bioAffinity CyPath Lung unit sales nearly 300% higher in April 2026 vs 2025

bioAffinity Technologies, Inc.

Record monthly CyPath Lung unit sales in April 2026; preliminary data shows ~300% YoY increase over April 2025.
Sales growth so far in 2026 exceeds internal projections, reflecting accelerating physician adoption.
CyPath Lung uses flow cytometry + AI for noninvasive lung cancer detection; 92% sensitivity, 87% specificity in trial.
Company advancing longitudinal clinical study, expanding use for lung cancer survivor monitoring, and R&D pipeline for asthma/COPD.
CEO Maria Zannes highlights CyPath Lung's role in risk stratification and nodule management.

item 8.01item 9.01

Source: SEC EDGAR

accession 0001493152-26-022428

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.